Human cryptosporidiosis.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Human cryptosporidiosis.

Int J STD AIDS. 1996;7 Suppl 1:28-33. Unique Identifier : AIDSLINE MED/96230318
Hoepelman IM; Department of Medicine, Eijkman Winkler Laboratory for Medical; Microbiology, University Hospital, Utrecht, The Netherlands.

Abstract: Cryptosporidium parvum is a protozoan which can cause severe debilitating disease in immunocompromised individuals. Animal models have shown that cellular immunity is the most important factor against the development of the disease. Individuals with a humoral immune deficiency are also at risk. In HIV-infected patients there is a clear relationship between disease severity and CD4 cell counts. Insight into the pathogenesis and development of new agents is hampered by the lack of an in vitro culture system. Prevention is of the utmost importance due to the difficulties of therapy and the severity of clinical disease which can develop. Oocysts are highly resistant to commonly used disinfectants. In HIV-infected patients with cryptosporidiosis, antiretroviral therapy should be instituted or modified. Moreover, non-specific therapy with antidiarrhoeal agents should also be instituted. If no effect is seen, therapy with paromomycin 500 mg 4 times daily for 2-3 weeks should be initiated, followed by maintenance therapy with 500 mg twice daily to prevent relapse.

Keywords: Animal Antibiotics, Macrolide/THERAPEUTIC USE Azithromycin/THERAPEUTIC USE AIDS-Related Opportunistic Infections/DRUG THERAPY Cryptosporidiosis/COMPLICATIONS/*DRUG THERAPY/PARASITOLOGY/ TRANSMISSION *Cryptosporidium parvum/PATHOGENICITY Human Mice JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
961030
M96A1420

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .